2nd Edition of International Cancer Research Conference
March 19-21, 2026 | Singapore
Cancer Neoantigens
Cancer neoantigens are novel peptides presented by cancer cells that arise from tumor-specific mutations. Unlike normal cellular proteins, these neoantigens are recognized as foreign by the immune system, making them promising targets for cancer immunotherapy. Neoantigen-based therapies, such as personalized cancer vaccines and adoptive T-cell transfer, aim to harness the body’s immune response to selectively attack tumor cells while sparing healthy tissue. Recent advances in genomics and bioinformatics have accelerated the identification and validation of neoantigens, paving the way for highly individualized treatments. These therapies hold potential for improved efficacy and reduced toxicity compared to traditional cancer treatments, marking a significant advancement in personalized oncology.
Rajvir Dahiya
University of California San Francisco, United States
Anyou Wang
DIFIBER LLC, United States
Michael Thompson
University of Toronto, Canada
Can Küçük
Dokuz Eylul University, Turkey
Nadia Leney Olazo Marquez
Benemérita Universidad Autónoma de Puebla, Mexico
Liu Ying
Shanghai University, China
Ratan Kumar Sarkar
Independent Researcher, IndiaSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : A case-based approach using IMPeTUs criteria in FDG PET/CT reporting of multiple myeloma
Mudalsha Ravina, All India Institute of Medical Sciences, India
Title : Transforming cancer care: Innovations, integrations, and impact
Shayan Maqsood, Jamia Hamdard University, India
Title : Updates on controversies surrounding the staging and management of newly diagnosed localized prostate cancer using prostate-specific membrane antigen (PSMA) positron emission tomography
Patricia Tai, University of Saskatchewan, Canada
Title : Advanced nanoparticles, the hallmark of targeted drug delivery for osteosarcoma
Shayan Maqsood, Jamia Hamdard University, India